TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30157913
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered at the same volume and infusion rate during the same time points.
Study: 26946617
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of cervus and cucumis polypeptides
Study: 26946617
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and rehabilitation exercises (Control)
Study: 22382341
Drug: CE-224,535 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-224,535 (500 mg bid)
Study: 19727904
Drug: 67.5 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67.5 mmol of bicarbonate daily for 3 months
Study: 10752972
Drug: Delavirdine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine treatment
Study: 8883526
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 mg I/ml (IOD-270)
Study: 8883526
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mg I/ml (IOD-320)
Study: 8883526
Drug: Iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 300 mg I/ml (IOH-300)
Study: 3984919
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of ascorbic acid for 1 day followed by 250 mg/day for 2 days
Study: 3984919
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of ascorbic acid for 1 day followed by 500 mg/day for 2 days
Study: 3984919
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of ascorbic acid for 1 day followed by 1000 mg/day for 2 days
Study: 3984919
Drug: unsupplemented for
Approvals — FDA: no, EMA: no, PMDA: no
Description: unsupplemented for 1 day followed by 0 mg ascorbic acid supplement for 2 days
Study: 3984919
Drug: unsupplemented for
Approvals — FDA: no, EMA: no, PMDA: no
Description: unsupplemented for 1 day followed by 90 mg ascorbic acid supplement for 2 days
Study: 30894226
Drug: Cerebral tissue
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral tissue oxygen saturation (crSO2) monitoring combined with defined treatment guidelines
Study: 30894226
Drug: Standard monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monitoring and treatment as usual
Study: 30894226
Drug: Defined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defined treatment guidelines
Study: 25539986
Drug: Microinjections of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microinjections of HA salts of biotechnological origin, once weekly for 4 weeks and then once monthly for 4 months (group A) or 9 months (group B)
Study: 25539986
Drug: Microinjections of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microinjections of HA salts of biotechnological origin, after an additional 4 months of monthly injections
Study: 25539986
Drug: Microinjections of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microinjections of HA salts of biotechnological origin, in patients from group B that completed 10 months of treatment
Study: 25539986
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injected into the dorsum of the other hand (control)
Study: 23451990
Drug: nHA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHA with 24% EDTA treatment
Study: 23451990
Drug: Composite graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite graft of nHA and β‐TCP with 24% EDTA treatment
Study: 19057413
Drug: Olanzapine (2.5-20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5-20.0 mg/day)
Study: 11238495
Drug: MK-677 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 (25 mg) plus alendronate (10 mg)
Study: 2977527
Drug: Zoladex (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (3.6 mg depot administered every four weeks for 3 times)
Study: 2977527
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (300 mg diethylstilbestrol diphosphate orally daily for 12 weeks or orchidectomy)
Study: 26631691
Drug: Oral moisturizing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral moisturizing jelly (OMJ)
Study: 22922775
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) 40 mg/m²/day for 28 days
Study: 22922775
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 6 mg/m²/day for 28 days
Study: 11246736
Drug: Cisplatin-based combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combination chemotherapy
Study: 18685360
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a third agent to doublet combinations
Study: 18685360
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs (pemetrexed and vinflunine)
Study: 10442371
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/day) plus oral calcium folinate (90 mg/day) and vinorelbine (15 mg/m2)
Study: 7531223
Drug: PVP16B (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP16B (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5 + bleomycin 30 IU/wk for 9 consecutive weeks)
Study: 7531223
Drug: PVP16 (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP16 (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5)
Study: 2193271
Drug: estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estrone sulfate 0.625 mg
Study: 2193271
Drug: estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estrone sulfate 1.25 mg
Study: 387204
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 FU infusion with mitomycin-C
Study: 387204
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 FU infusion with methyl-CCNU
Study: 31389859
Drug: Group A1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A1 (80 kVp, 40 mL CM, iterative reconstruction)
Study: 31389859
Drug: Group A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A2 (80 kVp, 40 mL CM, AI-based noise reduction)
Study: 31389859
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (120 kVp, 80 mL CM, iterative reconstruction)
Study: 29995458
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g/day) for 6 days
Study: 25185586
Drug: Individualised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised physical activity on prescription
Study: 16388724
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine (250 mg/day) for 6 weeks
Study: 1537129
Drug: Alteplase plus
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase plus heparin
Study: 1537129
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with adequate anticoagulation
Study: 1537129
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with patent vessels
Study: 1537129
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with recurrent ischemia
Study: 1537129
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with left ventricular thrombosis
Study: 27460620
Drug: Group Coping-Oriented
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Coping-Oriented Therapy (COP)
Study: 27460620
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy (SUP)
Study: 20393432
Drug: Rotigotine, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine, a dopaminergic drug, dosage and duration not specified
Study: 15714982
Drug: Docetaxel as
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel as a single agent
Study: 15714982
Drug: Docetaxel combined
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel combined with estramustine or other antimicrotubular agents
Study: 15714982
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with prednisone
Study: 10377207
Drug: fluticasone metered
Normalized name: fluticasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone metered dose inhaler (pMDI) 250 microg, 8 puffs
Study: 8710072
Drug: Tacrine >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine > 80 mg/d
Study: 8710072
Drug: Tacrine >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine > 120 mg/d
Study: 2029947
Drug: Clinic school
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic school focusing on high-risk youth and dispensing birth control pills
Study: 21285532
Drug: Newly-licensed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly-licensed vaccine (Fluarix™)
Study: 21285532
Drug: Established vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established vaccine
Study: 19583486
Drug: Fluoxetine in
Normalized name: Product containing fluoxetine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine in patients with normal thyroid function (n=15)
Study: 19583486
Drug: Sertraline in
Normalized name: Product containing sertraline in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline in patients with normal thyroid function (n=14)
Study: 19583486
Drug: Fluoxetine in
Normalized name: Product containing fluoxetine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine in patients with hypothyroidism (n=13)
Study: 19583486
Drug: Sertraline in
Normalized name: Product containing sertraline in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline in patients with hypothyroidism (n=15)
Study: 19583486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=10) with hypothyroidism on levothyroxine therapy without depression
Study: 3169222
Drug: Non-treatment (air
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (air without nebulizer)
Study: 23453404
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg single dose)
Study: 23453404
Drug: Everolimus (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (adjusted doses based on Child‐Pugh classification)
Study: 23453404
Drug: Thresholds for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thresholds for dose adjustment
Study: 17121506
Drug: Intervention pharmacists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention pharmacists received video-conference training on the management of depression and provided medication with extra advice and support.
Study: 15249281
Drug: Melatonin 1
Normalized name: melatonin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 1 mg nightly for 4 weeks
Study: 8482063
Drug: NSAID +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID + misoprostol 200 mcg bid
Study: 3688315
Drug: Trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (200 mg) twice/day for 5 days
Study: 3688315
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of trimethoprim (600 mg)
Study: 25882325
Drug: Brexpiprazole 4
Normalized name: brexpiprazole 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 4 mg
Study: 25682550
Drug: Brexpiprazole 1
Normalized name: brexpiprazole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 1 mg
Study: 25882325
Drug: Brexpiprazole 2
Normalized name: brexpiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 2 mg
Study: 21967319
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of gel mat
Study: 21967319
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel mat
Study: 16337459
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Study: 15317401
Drug: Subcutaneous fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous fondaparinux 2.5 mg once/day
Study: 9650328
Drug: Acarbose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (200 mg)
Study: 9650328
Drug: Plantago psyllium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago psyllium mucilage (15 g)
Study: 7661413
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization with albuterol (15 mg/hour)
Study: 7661413
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) with spacer device delivering albuterol
Study: 2797066
Drug: Furosemide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (4 ml; 10 mg per milliliter)
Study: 740584
Drug: Cyclical 'high-dose'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical 'high-dose' oestrogens
Study: 740584
Drug: Cyclical 'low-dose'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical 'low-dose' oestrogens
Study: 740584
Drug: Cyclical-sequential oestrogen/progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical-sequential oestrogen/progestogen regimens
Study: 740584
Drug: Overall hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overall hormonal therapy
Study: 26069178
Drug: Docetaxel, Cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel, Cisplatin, and 5‐FU (TPF) induction chemotherapy followed by surgery
Study: 21910821
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (60 units/kg body weight)
Study: 21910821
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (60 units/kg body weight) with concomitant use of acetylsalicylic acid (ASA)
Study: 16457909
Drug: HTMV without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HTMV without further DTP doses
Study: 12629336
Drug: Combination pneumatic/ultrasonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pneumatic/ultrasonic lithotrite
Study: 9075663
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (750 mg/day) and endoscopic dilation of major duct stenoses
Study: 3527809
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg i.v. dose of methylprednisolone sodium succinate (MPSS) followed by an identical dose three hours later in Study Group 2.
Study: 31654312
Drug: Drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone (DRSP) containing oral contraceptives (3 mg DRSP/30 mcg EE)
Study: 31654312
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) containing oral contraceptives (2 mg CMA/30 mcg EE)
Study: 29502087
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention group attended an antenatal diabetes clinic, commenced daily home blood glucose monitoring, and medication prescribed if lifestyle measures failed.
Study: 29502087
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with lifestyle education and a 75 g oral glucose tolerance test at 24 weeks' gestation.
Study: 21999637
Drug: TELEmonitoring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELEmonitoring device for medication adherence support used for six months in addition to usual care.
Study: 21999637
Drug: TELEmonitoring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELEmonitoring device for medication adherence support.
Study: 18488807
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of spironolactone (100 mg)
Study: 18488807
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of spironolactone (100 mg)
Study: 18488807
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of canrenone (active metabolite)
Study: 18488807
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of canrenone (active metabolite)
Study: 17726806
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 micrograms every 4 hours until termination of pregnancy
Study: 17726806
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 micrograms every 4 hours until termination of pregnancy
Study: 10709412
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I antiarrhythmic drugs
Study: 8881094
Drug: Performance-based exposure
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance-based exposure treatment
Study: 8881094
Drug: Combined cognitive/performance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive/performance treatment
Study: 1555416
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration during apneas
Study: 29161376
Drug: One-phase treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-phase treatment group (fixed appliance only)
Study: 29161376
Drug: Two-phase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-phase treatment group (removable appliance before fixed appliance)
Study: 29071932
Drug: Cobalamin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalamin (1 mL) injection
Study: 29071932
Drug: Gangliosides (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gangliosides (1 mL) injection
Study: 29071932
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication and rehabilitation training (Control)
Study: 24990160
Drug: Acupuncture (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (12 treatments over 8 weeks, twice weekly for 4 weeks then once weekly for 4 weeks)
Study: 12728156
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.15 mg/kg 6 hourly for 48 hours)
Study: 7566608
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of analgesic mixtures for at least 5 years
Study: 31002283
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy (spa bathing at ∼39°C, 3‐5 days/wk for ≤30 min, followed by ≤30 min of callisthenics)
Study: 23583255
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training plus simvastatin (40 mg/day)
Study: 21778330
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg daily for 3 months)
Study: 19801948
Drug: L-asparaginase (L-asp)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase (L-asp) therapy, median 5.5 doses (range: 1 to 20 doses)
Study: 19801948
Drug: L-asparaginase (L-asp)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase (L-asp) therapy
Study: 19801948
Drug: No L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L-asparaginase therapy (control group)
Study: 19801948
Drug: High-risk chemotherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk chemotherapy regimen
Study: 11748517
Drug: Nicardipine 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 0.015 mg/kg
Study: 11748517
Drug: Nicardipine 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 0.03 mg/kg
Study: 9269506
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with modified Phleum pratense allergenic extracts
Study: 9269506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with specific IT, only drugs)
Study: 24372434
Drug: Transurethral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral injection of Bulkamid®
Study: 1662595
Drug: Monthly norethisterone
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly norethisterone enanthate 50 mg + estradiol valerate 5 mg (injectable)
Study: 7114004
Drug: Indomethacin therapy
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin therapy (n = 13)